C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

Pharma Press Releases

Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.

Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept (“PoC”) Agreement for Two Ophthalmic Drug Candidates

Wednesday, March 31, 2021

Nanoform Finland Plc an innovative nanoparticle medicine enabling company and Nacuity Pharmaceuticals a Texasbased clinical stage pharmaceutical company today announced that they have signed a Technology Proof of Concept PoC Agreement with compensati...

European Commission Approves mAbxience’s Bevacizumab For The Treatment Of Certain Types Of Cancer

Wednesday, March 31, 2021

The European Commission EC has approved mAbxiences MB biosimilar to Avastin Bevacizumab in EuropeMB to be commercialized as Alymsys and Oyavas is highly similar to the reference medicinal product and data has shown a comparable quality safety and eff...

Charles River Laboratories Acquires Retrogenix

Wednesday, March 31, 2021

Charles River Laboratories International Inc announced today that it hasacquired Retrogenix Limited an earlystage contract research organization CRO providing specialized bioanalytical services utilizing its proprietarycell microarray technology

China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)

Wednesday, March 31, 2021

Zai Lab an innovative commercialstage biopharmaceutical company and Deciphera Pharmaceuticals NASDAQ DCPH a commercialstage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer

FDA approves Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Wednesday, March 31, 2021

The US Food and Drug Administration FDA has approved Sarclisa isatuximabirfc in combination with carfilzomib and dexamethasone Kd for the treatment of adult patients with relapsed or refractory multiple myeloma RRMM who have received one to three pri...

Amgen to Acquire Rodeo Therapeutics Corporation

Tuesday, March 30, 2021

Amgen Inc and Rodeo Therapeutics Corporation Rodeo today announced an agreement under which Amgen will acquire Rodeo a privately held biopharmaceutical company based in Seattle that develops smallmolecule therapies designed to promote regeneration an...

U.S. FDA Accepts AbbVie's New Drug Application for Atogepant for the Preventive Treatment of Migraine

Tuesday, March 30, 2021

AbbVie today announced that the US Food and Drug Administration FDA has accepted its New Drug Application NDA for atogepant an investigational orally administered calcitonin generelated peptide CGRP receptor antagonist gepant for the preventive treat...

Novartis receives EU approval for Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis

Tuesday, March 30, 2021

Novartis announced today that the European Commission has approved Kesimpta ofatumumab for the treatment of relapsing forms of multiple sclerosis RMS in adults with active disease defined by clinical or imaging features Kesimpta is a targeted

Merck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA® (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in

Tuesday, March 30, 2021

Merck known as MSD outside the United States and Canada today announced that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has adopted a positive opinion recommending that the European label for KEYTRUDA

Roche’s Evrysdi approved by European Commission as first and only at home treatment for spinal muscular atrophy

Tuesday, March 30, 2021

Roche today announced that the European Commission EC has approved Evrysdi risdiplam for the treatment of q spinal muscular atrophy SMA in patients two months of age and older with a clinical diagnosis of SMA Type Type or Type or with one to four...